PMID- 29077146
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 21
IP  - 19
DP  - 2017 Oct
TI  - Study on the effect of different doses of rosuvastatin on ventricular remodeling 
      in patients with acute coronary syndrome after emergency percutaneous coronary 
      intervention.
PG  - 4457-4463
LID - 13522 [pii]
AB  - OBJECTIVE: The objective of the present study was to observe the effects of 
      different doses of rosuvastatin on cardiac protection in patients with acute 
      coronary syndrome (ACS) after stent implantation. PATIENTS AND METHODS: A total 
      of 137 patients with ACS were selected from March 2014 to January 2015 and 
      randomly divided into: 1. The conventional treatment group: 45 patients were 
      treated with conventional drugs such as aspirin, clopidogrel, nitrates, and a 
      beta-blocker; 2. The conventional rosuvastatin dose group: 45 patients received 10 
      mg/d rosuvastatin before sleep in addition to routine therapy; 3. The large 
      rosuvastatin dose group: 47 patients received 20 mg/d rosuvastatin before sleep 
      in addition to routine therapy. The course of treatment was 12 weeks. At 1, 6, 
      and 12 week, ultrasound echocardiography, electrocardiogram (ECG), 
      high-sensitivity C-reactive protein (hs-CRP), and pro-brain natriuretic peptide 
      (pro-BNP) levels were tested to evaluate the therapeutic effects. The ultrasonic 
      imaging criteria included left ventricular end diastolic diameter (LVEDD), left 
      ventricular end systolic diameter (LVESD), left ventricular end diastolic volume 
      (LVEDV), left ventricular end systolic volume (LVESV), and left ventricular 
      ejection fraction (LVEF). RESULTS: After 1 week, hs-CRP, pro-BNP, and 
      echocardiography of the patients in the three groups showed no significant 
      differences (p>0.05); after 6 and 12 weeks, the levels of hs-CRP, MMP-9, and 
      pro-BNP in the large rosuvastatin dose group were significantly lower than in the 
      conventional rosuvastatin dose group and conventional treatment group (p<0.05), 
      and ultrasonic indexes changed significantly after 12 weeks (p<0.05). There were 
      no significant differences in ultrasonic indexes after 6 weeks (p>0.05). No 
      thrombosis or restenosis occurred during the follow-up period in each group. 
      CONCLUSIONS: Three months after emergency percutaneous coronary intervention, a 
      high-dose of rosuvastatin can delay ventricular remodeling, effectively inhibit 
      malignant remodeling of the heart, improve left ventricular systolic function, 
      reduce the prevalence of adverse events, and significantly improve the long-term 
      prognosis.
FAU - Guo, J
AU  - Guo J
AD  - Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, 
      Shandong Province, China. zhang_wenzhong1@163.com.
FAU - Zhang, W-Z
AU  - Zhang WZ
FAU - Zhao, Q
AU  - Zhao Q
FAU - Wo, J-S
AU  - Wo JS
FAU - Cai, S-L
AU  - Cai SL
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy/surgery/*therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*methods
MH  - Rosuvastatin Calcium/*therapeutic use
MH  - Stroke Volume/drug effects
MH  - Ventricular Remodeling/*drug effects
EDAT- 2017/10/28 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/10/28 06:00
PHST- 2017/10/28 06:00 [entrez]
PHST- 2017/10/28 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
AID - 13522 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2017 Oct;21(19):4457-4463.